Insights

Compound Library Consortium

icons/content-types/white paper white paper

Discovery

The creation of high-quality, innovative small molecule leads is a continual challenge in drug discovery. Against a background of increasing cost, the rate of drug discovery has remained stagnant for over 60 years. Improving research and development productivity is a considerable obstacle for the pharmaceutical sector. To address these challenges, innovative methods are crucial. Curia addresses this in a novel way through CLC.

View resource 0088AE5F-29AA-4BF7-826D-52FA93D463D0

Ready to move from idea to impact?

Whether you have a question for our team or an opportunity you’re eager to pursue, one of our experts can help you get started.

Contact Us
More from Curia

icons/content-types/white paper white paper

Revolutionizing Small Molecule API Production:
Unveiling the Impact of Fermentation as a Sustainable Solution

While large molecules continue to advance in drug development pipelines, small molecule Active Pharmaceutical Ingredients (APIs) still retain their historical dominance among new drug applications (NDAs). However, the last few years have seen the lin...

icons/content-types/white paper white paper

FDA's Quality Management Maturity Program:
Why should CDMOs adhere to the new CDER's Rating System?

Ensuring the safety and efficacy of pharmaceutical products is paramount in the healthcare industry, making the FDA's Quality Management Maturity (QMM) program and CDER's proposed rating system crucial for Contract Development and Manufacturing Organ...